Megan Waiters can recite the stories of dozens of people she has helped connect to the internet in western Alabama. A 7-year-old who couldn’t do classwork online without a tablet, and the 91-year-old she taught to check health care portals on a smartphone. “They have health care needs, but they don’t have the digital skills,”…
If you or someone you know may be experiencing a mental health crisis, contact the 988 Suicide & Crisis Lifeline by dialing or texting “988.” ASHEVILLE, N.C. — A few months ago, Waynesville Police Sgt. Paige Shell was about to give up hope of getting better. The daily drip of violence, death, and misery from…
DUOS’ $130 million raise was led by FTV Capital and included participation from Forerunner Ventures. The post DUOS Snags $130M to Advance AI, Grow Payer Partnerships appeared first on MedCity News.
Epic says MyChart Central simplifies the user experience with a single sign-in and a united view across organizations
This Peterson-KFF Health System Tracker chart collection examines trends in employee spending on deductibles, copayments, and coinsurance from 2012 to 2023 using a sample of health benefit claims for individuals under 65.
The Host Julie Rovner KFF Health News @jrovner @julierovner.bsky.social Read Julie’s stories. Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health policy news podcast, “What the Health?” A noted expert on health policy issues, Julie is the author of the critically praised reference book “Health Care Politics and Policy A…
The Host Julie Rovner KFF Health News @jrovner @julierovner.bsky.social Read Julie’s stories. Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health policy news podcast, “What the Health?” A noted expert on health policy issues, Julie is the author of the critically praised reference book “Health Care Politics and Policy A…
Bain/KLAS survey shows 70 percent of providers and 80 percent of payers have an AI strategy either in place or in development
Novo Nordisk is acquiring Akero Therapeutics for drug candidate efruxifermin, which executive say could be first and best in the emerging class of FGF21 analogs for the fatty liver disease MASH. The deal comes months after Novo’s internal FGF21 drug candidate failed a Phase 2 trial. The post With $4.7B Akero Acquisition, Novo Nordisk Maps…
Novo Nordisk is acquiring Akero Therapeutics for drug candidate efruxifermin, which executive say could be first and best in the emerging class of FGF21 analogs for the fatty liver disease MASH. The deal comes months after Novo’s internal FGF21 drug candidate failed a Phase 2 trial. The post With $4.7B Akero Acquisition, Novo Nordisk Maps…